Intuitive Surgical delivered a substantial top-line beat in the third quarter of 2026, with revenue growing 22% year-over-year driven by procedure volume and the continued rollout of the da Vinci 5 system. While GAAP results were impacted by a $450 million one-time antitrust litigation settlement, core operational performance remained robust across multi-port and endoluminal platforms.
Key Highlights
- Non-GAAP EPS of $3.00 significantly exceeded the analyst estimate of $2.13, representing 25% growth over the prior year.
- System placements accelerated to 546 units, including 315 next-generation da Vinci 5 systems, compared to 427 total systems in the third quarter of 2025.
- The total installed base for da Vinci surgical systems expanded to 12,094 units, a 12% increase, while the Ion endoluminal base grew 21% to 1,152 units.
- Management reached a $450 million settlement to resolve class action antitrust litigation, resulting in a $0.99 per share net-of-tax impact on GAAP earnings.